PRDX6 and lung carcinoma: To test whether interaction between thiacremonone and PRDX6 could attenuate prdx6-mediated promoter activity and expression, the cells were treated with thiacremonone (10, 20, and 50 μg/ml) for 6 hrs in A549 and NCI-H460 human lung cancer cells transfected with a prdx6-dependent luciferase reporter construct.